{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-78.5","upperLimit":"103.0","value":"-7.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Percent prolactin change from start of lapatinib to end of study participant participation","dispersionType":"Full Range","groups":[{"description":"All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study.\n\nLapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.","id":"OG000","title":"Lapatinib"}],"paramType":"MEDIAN","populationDescription":"Prolactin results only reported on the 6 prolactinomas in the trial and not for the nonfunctioning tumors.","reportingStatus":"POSTED","timeFrame":"Baseline and at 6 months","title":"% Change in Prolactin From Baseline to Study End","type":"SECONDARY","unitOfMeasure":"percent change in prolactin"}